palopegteriparatide: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
palopegteriparatide: clinical details
Prescribing considerations
- Initiation and monitoring should be led by a professional experienced in chronic hypoparathyroidism.
- Ensure serum calcium is stable and 25-hydroxyvitamin D is within the normal range before initiation.
- Coordinate changes to active vitamin D and calcium supplementation using biochemical results.
- Abrupt interruption can cause hypocalcaemia.
Contraindications and cautions
- Hypersensitivity to palopegteriparatide or an excipient.
- Pseudohypoparathyroidism.
- Use caution with severe renal or hepatic impairment and in people at increased baseline risk of osteosarcoma.
Monitoring
- Serum calcium during initiation, after relevant treatment changes and during maintenance.
- Clinical features of hypo- or hypercalcaemia.
- 25-hydroxyvitamin D and renal function as clinically appropriate.
- Cardiac glycoside concentrations and toxicity signs when relevant.
- Bone health in people at increased fragility-fracture risk.
Clinical pharmacology
A transiently pegylated PTH(1-34) prodrug that undergoes controlled linker cleavage, providing sustained exposure to active PTH. PTH1-receptor activation affects renal calcium and phosphate handling, active vitamin D synthesis and bone turnover.
Formulation and product differences
- Clear, colourless solution supplied in multidose disposable pre-filled pens.
- Pen strengths use different colour-coded labels and push buttons; the selected presentation is blue-coded.
- Pens are for one patient only and are stored without a needle attached between injections.
palopegteriparatide preparations and strengths
Injection
Route: Parenteral
Strengths: 168 micrograms/0.56 mL, 294 micrograms/0.98 mL, 420 micrograms/1.4 mL
palopegteriparatide interactions
Formal interaction studies have not been performed. Medicines affecting calcium can alter the response to palopegteriparatide.
Digoxin, digitoxin and other cardiac glycosides
High calcium can increase cardiac glycoside toxicity; calcium, medicine levels and toxicity symptoms may require monitoring.
Bisphosphonates, denosumab or romosozumab
These bone treatments can alter blood calcium and the response to palopegteriparatide.
Thiazide or loop diuretics
These can change blood calcium, so additional monitoring may be needed.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.